AbbVie 2013 Annual Report Download - page 36

Download and view the complete annual report

Please find page 36 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

14FEB201404102302
COMPARISON OF CUMULATIVE TOTAL RETURN
$100
$125
$150
$175
1/2/2013 3/31/2013 6/30/2013 9/30/2013 12/31/2013
AbbVie Inc. S&P 500 Index NYSE Arca Pharmaceutical Index
This performance graph is furnished and shall not be deemed ‘‘filed’’ with the SEC or subject to
Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any of our filings
under the Securities Act of 1933, as amended.
Issuer Purchases of Equity Securities
(c) Total
Number of
Shares (or Units)
(a) Total Purchased as Part (d) Maximum Number (or
Number (b) Average of Publicly Approximate Dollar Value) of
of Shares Price Announced Shares (or Units) that May
(or Units) Paid per Share Plans or Yet Be Purchased Under the
Period Purchased (or Unit) Programs Plans or Programs
October 1, 2013 - October 31,
2013 23,424(1) $48.16 0 $1,478,178,553(2)
November 1, 2013 -
November 30, 2013 27,503(1) $48.60 0 $1,478,178,553(2)
December 1, 2013 -
December 31, 2013 3,860,352(1) $52.83 3,795,945 $1,277,633,716(2)
Total 3,911,279(1) $52.77 3,795,945 $1,277,633,716(2)
(1) These shares represent:
(i) the shares deemed surrendered to AbbVie to pay the exercise price in connection with the
exercise of employee stock options—23,424 in October; 16,203 in November; and 51,107 in
December; and
(ii) the shares purchased on the open market for the benefit of participants in the AbbVie
Employee Stock Purchase Plan—0 in October; 11,300 in November; and 13,300 in December.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding
obligations in connection with the vesting of restricted stock or restricted stock units.
(2) On February 15, 2013, AbbVie announced that its board of directors approved the purchase of up
to $1.5 billion of its common stock, from time to time.
32